This company has been marked as potentially delisted and may not be actively trading. Novus Therapeutics (NVUS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NVUS vs. NBY, MTNB, AEON, NRBO, AEZS, CPHI, OGEN, GRAY, SPRB, and ORGSShould you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include NovaBay Pharmaceuticals (NBY), Matinas Biopharma (MTNB), AEON Biopharma (AEON), NeuroBo Pharmaceuticals (NRBO), Aeterna Zentaris (AEZS), China Pharma (CPHI), Oragenics (OGEN), Graybug Vision (GRAY), Spruce Biosciences (SPRB), and Orgenesis (ORGS). These companies are all part of the "medical" sector. Novus Therapeutics vs. Its Competitors NovaBay Pharmaceuticals Matinas Biopharma AEON Biopharma NeuroBo Pharmaceuticals Aeterna Zentaris China Pharma Oragenics Graybug Vision Spruce Biosciences Orgenesis NovaBay Pharmaceuticals (NYSE:NBY) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership. Does the media favor NBY or NVUS? In the previous week, NovaBay Pharmaceuticals' average media sentiment score of 0.00 equaled Novus Therapeutics'average media sentiment score. Company Overall Sentiment NovaBay Pharmaceuticals Neutral Novus Therapeutics Neutral Which has better earnings and valuation, NBY or NVUS? NovaBay Pharmaceuticals has higher revenue and earnings than Novus Therapeutics. Novus Therapeutics is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovaBay Pharmaceuticals$9.78M1.54-$9.64M-$53.72-0.05Novus TherapeuticsN/AN/A-$16.01M-$21.58-0.12 Do institutionals and insiders believe in NBY or NVUS? 23.3% of NovaBay Pharmaceuticals shares are owned by institutional investors. 0.1% of NovaBay Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of Novus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is NBY or NVUS more profitable? Novus Therapeutics has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. Novus Therapeutics' return on equity of -133.49% beat NovaBay Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NovaBay Pharmaceuticals-102.72% -7,293.78% -158.41% Novus Therapeutics N/A -133.49%-30.52% Which has more volatility and risk, NBY or NVUS? NovaBay Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Do analysts rate NBY or NVUS? NovaBay Pharmaceuticals currently has a consensus target price of $0.85, indicating a potential downside of 67.18%. Given NovaBay Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe NovaBay Pharmaceuticals is more favorable than Novus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovaBay Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Novus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryNovaBay Pharmaceuticals beats Novus Therapeutics on 7 of the 13 factors compared between the two stocks. Get Novus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVUS vs. The Competition Export to ExcelMetricNovus TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.65M$931.52M$5.86B$10.15BDividend YieldN/A4.84%5.68%4.59%P/E Ratio-0.111.1074.5225.93Price / SalesN/A26.70539.62123.65Price / CashN/A19.5637.5660.44Price / Book0.196.6912.166.29Net Income-$16.01M-$4.50M$3.28B$270.77M Novus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVUSNovus TherapeuticsN/A$2.54-1.9%N/A+1.2%$3.65MN/A-0.117High Trading VolumeNBYNovaBay Pharmaceuticals0.4182 of 5 stars$2.54+42.7%$0.85-66.5%+513.4%$10.37M$9.78M-0.0530Gap UpHigh Trading VolumeMTNBMatinas Biopharma0.1275 of 5 stars$1.83+0.5%N/AN/A$9.31MN/A-0.3830Negative NewsShort Interest ↑AEONAEON Biopharma3.1423 of 5 stars$0.74+1.5%$360.00+48,352.2%-98.6%$8.65MN/A4.135News CoveragePositive NewsShort Interest ↓Gap DownNRBONeuroBo PharmaceuticalsN/A$0.63-2.0%N/A-81.9%$5.46MN/A0.0010AEZSAeterna ZentarisN/A$3.04-4.0%N/A-24.9%$5.45M$2.37M-0.2020Gap DownCPHIChina PharmaN/A$1.42+2.2%N/A-92.0%$4.63M$4.40M0.00250News CoverageOGENOragenics0.1993 of 5 stars$1.05+1.9%N/A-92.3%$4.33MN/A-0.155Negative NewsShort Interest ↑Gap DownGRAYGraybug VisionN/A$2.70-1.1%N/A-28.3%$4.24MN/A-1.5627High Trading VolumeSPRBSpruce Biosciences1.8567 of 5 stars$7.00-6.7%$131.25+1,775.0%-75.0%$3.93M$4.91M-7.4520Gap DownORGSOrgenesisN/A$0.80-20.0%N/AN/A$3.84M$662K0.00150Gap Down Related Companies and Tools Related Companies NBY Alternatives MTNB Alternatives AEON Alternatives NRBO Alternatives AEZS Alternatives CPHI Alternatives OGEN Alternatives GRAY Alternatives SPRB Alternatives ORGS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVUS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
